Paul McBarron - 31 Jan 2023 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Role
E. VP, Fin, CFO, COO and Secretary, Director
Signature
/s/ Paul McBarron
Issuer symbol
CYCC
Transactions as of
31 Jan 2023
Net transactions value
$0
Form type
4
Filing time
02 Feb 2023, 15:19:39 UTC
Previous filing
15 Dec 2021
Next filing
03 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYCC Common Stock Award $0 +31,200 +10685% $0.000000 31,492 31 Jan 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person received an award of 31,200 restricted stock units on January 31, 2023, which shall vest in full on January 31, 2026, provided, however, that if certain clinical milestones are achieved then such restricted stock units shall vest in full earlier in connection with such achievement.
F2 Includes 292 shares of common stock and 31,200 restricted stock units.

Remarks:

E. VP, Fin, CFO, COO and Secretary